Cargando…
Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial
INTRODUCTION: Ixekizumab, an interleukin-17A antibody, has shown efficacy in non-radiographic axial spondyloarthritis (nr-axSpA). The objectives of this analysis were (a) to measure improvement in ixekizumab-treated patients in Assessment of Spondyloarthritis International Society (ASAS) response do...
Autores principales: | Deodhar, Atul, Mease, Philip, Rahman, Proton, Navarro-Compán, Victoria, Marzo-Ortega, Helena, Hunter, Theresa, Sandoval, David, Kronbergs, Andris, Leon, Luis, Shan, Mingyang, Leung, Ann, De Vlam, Kurt, Strand, Vibeke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991024/ https://www.ncbi.nlm.nih.gov/pubmed/33284423 http://dx.doi.org/10.1007/s40744-020-00254-z |
Ejemplares similares
-
Ixekizumab improves sleep and work productivity in patients with non-radiographic axial spondyloarthritis: results from the COAST-X trial at 52 weeks
por: Deodhar, Atul, et al.
Publicado: (2021) -
Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results
por: Deodhar, Atul A., et al.
Publicado: (2021) -
Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks
por: Marzo-Ortega, Helena, et al.
Publicado: (2020) -
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022) -
The role of ixekizumab in non-radiographic axial spondyloarthritis
por: San Koo, Bon, et al.
Publicado: (2021)